Table 1.
Demographic characteristics of our population.
| Total (N) | ||
|---|---|---|
| Sex | 45 | |
| Woman, n (%) | 15 (33.33) | |
| Man, n (%) | 30 (66.67) | |
| Age | ||
| Minimum | 26 | |
| Maximum | 85 | |
| Median | 69 | |
| Age at onset, mean (standard deviation) | 62.22 (16.32) | |
| MGFA class | ||
| I, n (%) | 0 (0) | |
| IIA, n (%) | 10 (22.2) | |
| IIB, n (%) | 14 (31.1) | |
| IIIA, n (%) | 5 (11.1) | |
| IIIB, n (%) | 9 (20) | |
| IV, n (%) | 5 (11.1) | |
| V, n (%) | 2 (4.4) | |
| Antibodies | ||
| Anti-RAch, n (%) | 41 (91.1) | |
| 0 (0) | ||
| Anti-MuSK, n (%) | 4 (8.9) | |
| Double seronegative, n (%) | 22 (48.9) | |
| Anti-striated muscle, n (%) | ||
| Thymus | ||
| Thymoma, n (%) | 2 (4.4) | |
| Thymic hyperplasia, n (%) | 4 (8.9) | |
| Atrophy or CT without evidence of thymoma, n (%) | 39 (86.7) | |
| Score on scales (pretreatment and at V1) | ||
| Pretreatment QMG, Mean (standard deviation) | 17.04 (3.83) | 25 |
| Pretreatment QMG, Median [25%, 75%] | 17 [14; 20] | 25 |
| V1 MG-QOL, Mean (standard deviation) | 25.93 (13.42) | 43 |
| V1 MG-QOL, Median [25%; 75%] | 23 [15; 36] | 43 |
| V1 ADL, Mean (standard deviation) | 5.84 (2.92) | 45 |
| V1 ADL, Median [25%; 75%] | 6 [4; 7] | 45 |
| V1 QMG, Mean (standard deviation) | 14.4 (3.63) | 45 |
| V1 QMG, Median [25%; 75%] | 14 [11; 16] | 45 |
| V1 MG-Composite, Mean (standard deviation) | 9.6 (5.44) | 45 |
| V1 MG-Composite, Median [25%; 75%] | 8 [6; 11] | 45 |
| V1 Neuro-QoL fatigue, Mean (standard deviation) | 44.44 (19.31) | 43 |
| V1 Neuro-QoL fatigue, Median [25%; 75%] | 39 [28.5; 59] | 43 |
Modified from Diez-Porras et al. 2020 [2]. Abbreviations: MGFA, Myasthenia Gravis Foundation of America; CT, computed tomography; QMG, Quantitative Myasthenia Gravis Scoring System; ADL, Myasthenia Gravis-Activities of Daily Living Profile; MG-Composite, Myasthenia Gravis-Composite Scale.